London-based HealthTech startup SheMed has secured €43 million in new funding to expand its personalized healthcare platform for women and strengthen its position as one of the UK’s fastest-growing players in digital health.
Founded in April 2024 by sisters Olivia and Chloe Ferro, SheMed has quickly built a community of more than 60,000 members, offering tailored medical programs that combine technology, clinical support, and data-driven insights. The company focuses on addressing long-standing gaps in women’s healthcare—particularly in metabolic and hormonal health—through continuous digital support and access to qualified clinicians.
“As a GLP-1 patient myself, I know how transformative the right diagnosis and treatment can be,” said Olivia Ferro, SheMed’s Co-founder and CEO. “We built SheMed to give women the personalized support I struggled to find: care that listens, understands, and empowers.”
Expanding Clinical and Tech Capabilities
The fresh capital will help SheMed scale its medical and technology teams, bolster clinical infrastructure, and expand across the UK. The startup also plans to deepen its data and research efforts, including new initiatives designed to improve access to high-quality, individualized care.
Later this month, SheMed will release results from the first-ever female-focused GLP-1 clinical study, exploring how these medications affect women’s hormonal and metabolic responses—a milestone expected to inform future treatment approaches.
“The demand for SheMed’s services has been extraordinary,” added Chloe Ferro, Co-founder and President. “Women are seeking care that recognizes their individuality, their biology, and their experiences. That’s exactly what SheMed delivers.”
Riding a Wave of HealthTech Investment
SheMed’s fundraise reflects broader momentum in preventative and personalized healthcare across the UK and Europe. The HealthTech sector has seen strong investor confidence throughout 2025, with UK startups collectively raising around €14.7 billion so far, according to EU-Startups.
Other players in adjacent areas have also drawn major funding this year—Numan (€51.6 million) to expand its digital healthcare services into women’s health, and Hormona (€7.8 million) for its AI-driven hormone tracking platform. Similar ventures like Perci Health and CoMind have likewise raised new rounds to accelerate personalized care solutions.
Redefining Women’s Health in the Digital Age
SheMed’s all-in-one platform integrates medical oversight, wellness tracking, and 24/7 patient support. Its flagship GLP-1 and weight-management program blends clinical expertise with continuous coaching, aiming to provide sustainable outcomes for women navigating hormonal and metabolic challenges.
In under a year, SheMed has established itself as the fastest-growing GLP-1 program in the UK, underscoring the growing demand for healthcare that is both evidence-based and empathetic.
With its new funding and expanding research agenda, SheMed is positioning itself at the forefront of data-driven women’s health innovation—and setting a new standard for how care can be delivered, personalized, and sustained in the digital era.
